Adjuvant exemestane more effective than tamoxifen if combined with

2014 ASCO Annual Meeting

Adjuvant exemestane more effective than tamoxifen if combined with ovarian function suppression in breast cancer

Listen now

Description

Dr Pagani talks to ecancertv at ASCO 2014 about the results of a landmark study that was a joint analysis of two phase III trials, TEXT and SOFT, which demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when given with ovarian function suppression in premenopausal women with hormone-sensitive cancers.

More Episodes

See all »

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 patients with advanced melanoma which showed that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.

Published 07/15/14

2014 ASCO Annual Meeting

Published 07/15/14

ASCO 2014 roundup

ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.

Published 07/11/14